撰文丨王聪 编辑丨王多鱼 排版丨水成文 血管性痴呆 （VaD） 约占所有痴呆病例的 25%，是仅次于 阿尔茨海默病 （AD） 的第二常见痴呆类型。值得注意的是，血管性痴呆 （VaD） 常与阿尔茨海默 病 （AD） 共存，84% 的老年人同时表现出血管性痴呆的形态特征和阿尔茨海默病的病理变化，表明这两种疾病可能存在累加或协同作用。 尽管血管性痴呆 （VaD） 的发病率很高，且对全球健康有着深远影响，但其潜在发病机制仍知之甚少。目前，尚无针对血管性痴呆 （VaD） 的直接治疗方法， 现有的对症疗法 （例如胆碱酯酶抑制剂和美金刚） 疗效有限，且未能针对潜在的血管病变。这些知识空白凸显了开展全面研究的紧迫性，以确定治疗靶点，并在 能准确模拟人类血管性痴呆 （VaD） 多样病因的动物模型中验证其可转化性。 2025 年 6 月 30 日 ， 加州大学洛杉矶分校 S. Thomas Carmichael 团队 （博士后 田敏 为第一作者） 在国际顶尖学术期刊 Cell 上发表了题为 ： Deconstructing the intercellular interactome in vascular dementia wi ...

Zimmer Biomet (ZBH) FY Conference June 09, 2025 09:20 AM ET Speaker0 Okay. Good morning, everyone. We'll go ahead and get started here. Very pleased to welcome Ivan Tornos, Chairman and CEO of Zimmer Biomet and Sukhi Upade, Executive Vice President and CFO. As with all of these sessions, if you have a question, feel free to raise your hand. I certainly have have plenty to keep us to keep us going here, but obviously, we wanna keep this as interactive as possible. So why don't we start with with a topic that ...

Ventyx Biosciences (VTYX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Don't worry, we would not miss this. Speaker1 Never a doubt, Mike. Speaker0 Good afternoon. I'm Michael Yee, a biotechnology analyst here at Jefferies. And very happy to moderate our next discussion with Ventix Biosciences. We have members of the of the team up here. We have Raju Mohan, CEO, and Matt Moore. Matt Moore. Fantastic. Maybe it would be a great opportunity, Raju, for you to just make some, broad opening comments. Ventix ...

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Bio ...

Haemonetics (HAE) Q4 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Olga Guyette - VP - Investor Relations & TreasurerChristopher Simon - CEO, President & DirectorJames D'Arecca - Executive VP & CFORohin Patel - Vice PresidentMarie Thibault - Managing DirectorAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorAnthony Petrone - Managing Director Conference Call Participants Mike Matson - Senior Equity Research AnalystMike Petusky - Research AnalystCraig Bijou - Equity Re ...

Financial Data and Key Metrics Changes - The company reported total revenue of $1.4 billion, reflecting a 4% growth on a reported basis and 1% organic growth, with organic growth excluding $148 million from CSL and the whole blood divestiture at 8% [7][8] - Adjusted gross margin for the fourth quarter was 60.2%, an increase of 620 basis points compared to the prior year, driven by volume growth and improved product mix [24][25] - Adjusted net income for fiscal year 2025 was $231.5 million, up $28 million or 14%, with adjusted earnings per diluted share at $4.57, a 15% increase compared to the prior year [29] Business Line Data and Key Metrics Changes - Hospital revenue grew 12% in the quarter and 24% in fiscal year 2025 on a reported basis, with organic growth of 9% respectively [11] - Blood Management Technologies revenue grew 6% in the quarter and 10% in fiscal year 2025, driven by strong utilization and share gains [11] - The Interventional Technologies franchise delivered 21% reported growth in the quarter and 46% in fiscal year 2025, with 16% organic growth respectively [13] Market Data and Key Metrics Changes - Plasma revenue declined 9% in the quarter and 6% in fiscal year 2025, but excluding CSL, plasma revenue grew 11% in the fourth quarter and 5% for fiscal year 2025 [18][20] - Blood center revenue declined 22% in the quarter and 8% in fiscal year 2025 on a reported basis due to the whole blood divestiture [21] - The company anticipates plasma revenue to decline 7% to 10% on a reported basis in fiscal year 2026, with organic growth excluding CSL expected to be 11% to 14% [20] Company Strategy and Development Direction - The company is focused on advancing its innovation agenda and reallocating resources towards higher growth opportunities following the divestiture of the whole blood business [28] - A new regional and market alignment initiative is expected to generate approximately $30 million of net savings over the next two years [28] - The company aims for both blood management technologies and interventional technologies to become billion-dollar franchises each [66] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the strong growth trajectory of the hospital business, projecting reported and organic revenue growth of 8% to 11% in fiscal year 2026 [16] - The company expects adjusted operating margin to improve by 200 to 300 basis points, reaching 26% to 27% in fiscal year 2026 [33] - Management highlighted the importance of cash flow generation and expects free cash flow in fiscal year 2026 to be in the range of $160 million to $200 million [35] Other Important Information - The company executed a $150 million share buyback, repurchasing approximately 2.4 million shares, reflecting its commitment to value creation [10] - The adjusted income tax rate was 22% for the fourth quarter and 23% for fiscal year 2025, compared to 21% to 23% for the respective periods of the prior year [28] Q&A Session Summary Question: Insights on plasma collections and guidance for fiscal year 2026 - Management remains bullish on plasma, indicating that the 11% to 14% growth guidance is primarily driven by share gains and technology adoption, with modest growth expected in the first half of fiscal year 2026 [43][45] Question: Clarification on EPS guidance and operating margin drivers - The operating margin guidance of 26% to 27% is supported by continued gross margin improvement and operational leverage, with a $0.20 impact from tariffs factored into the guidance [47][49] Question: Update on vascular closure portfolio and legacy business performance - The company is focusing on driving utilization and share gains in the vascular closure market, with a dedicated team addressing both new and legacy products [55][60] Question: Changes in strategy following management transitions - The leadership changes are aimed at enhancing focus on growth in the hospital segment, with expectations for both blood management and interventional technologies to reach billion-dollar franchises [66][67] Question: Update on M&A activities and potential acquisition of VIVUSURE Medical - The company maintains a long-term appetite for strategic acquisitions, with optimism regarding the VIVUSURE opportunity, which aligns with its focus on closure and structural heart segments [74][76]

Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized sci ...

Financial Data and Key Metrics Changes - The company reported a revenue guidance for the year between $6.2 billion and $6.3 billion, indicating a flat to slightly positive growth of $100 million or 1-2% year-over-year [32] - The company experienced higher transportation costs in the first part of the year but expects to lap these costs in the latter half [31] Business Line Data and Key Metrics Changes - The company is focusing on improving inventory productivity and reducing production lead times, particularly in underwear and Pink apparel [15][24] - The sport and swim categories are still relatively small but are seen as significant growth opportunities moving forward [55] Market Data and Key Metrics Changes - The warmer weather regions outperformed colder regions, indicating a weather impact on sales trends from late January through February [20] - International markets showed double-digit growth, with strong performance in franchise and travel retail markets, particularly in China [49][50] Company Strategy and Development Direction - The company is implementing a strategy to create separate tracks for product lines, aiming to reduce the traditional 52-week calendar for apparel [24] - Marketing strategies will differ between brands, with a focus on increasing consideration for Versus and improving customer engagement for Pink [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual improvements in business performance, driven by strategic changes and marketing efforts [8][5] - The company anticipates a more promotional environment compared to the previous year, particularly in traffic-driving categories [45] Other Important Information - The company has largely completed its three-year cost savings goal ahead of schedule, achieving nearly $200 million in savings in 2024 [40] - Management is conducting research to better understand consumer preferences before finalizing marketing strategies [60] Q&A Session Summary Question: Drivers of gradual improvement and product pipeline - Management indicated that improvements will come from team placements and marketing differentiation, but specifics on product launches were not disclosed [7][8] Question: Inventory productivity and production lead times - Management stated that they are in good shape regarding production lead times, especially in underwear and some Pink apparel areas [15] Question: Regional performance and customer demographics - Management noted that warmer regions performed better than colder ones, reflecting weather impacts on sales [20] Question: Strategy for product lines and Valentine's Day performance - Management emphasized the importance of multiple tracks for product lines and noted that Valentine's Day promotions were successful [24][23] Question: Guidance for the year and promotional activity - Management expects the guidance to improve throughout the year, with a plan for reduced promotional activity compared to the previous year [31][45] Question: International growth expectations - Management reported strong international performance with double-digit growth and positive comps in various markets [49][50] Question: Size and growth opportunity in sport and swim businesses - Management acknowledged that while these categories are small, they present significant growth potential [55] Question: Marketing focus and consumer research - Management is working on understanding consumer preferences before finalizing marketing strategies for the brands [60]